Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
von Minckwitz, G; Rezai, M; Fasching, P A; Huober, J; Tesch, H; Bauerfeind, I; Hilfrich, J; Eidtmann, H; Gerber, B; Hanusch, C; Blohmer, J U; Costa, S D; Jackisch, C; Paepke, S; Schneeweiss, A; Kümmel, S; Denkert, C; Mehta, K; Loibl, S; Untch, M 
Titel:
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). 
Abstract:
The GeparQuattro study showed that adding capecitabine or prolonging the duration of anthracycline-taxane-based neoadjuvant chemotherapy from 24 to 36 weeks did not increase pathological complete response (pCR) rates. Trastuzumab-treated patients with HER2-positive disease showed a higher pCR rate than patients with HER2-negative disease treated with chemotherapy alone. We here present disease-free (DFS) and overall survival (OS) analyses.Patients (n = 1495) with cT>= 3 tumors, or negative hormo...    »
 
Zeitschriftentitel:
Ann Oncol 
Jahr:
2014 
Band / Volume:
25 
Heft / Issue:
Seitenangaben Beitrag:
81-9 
Sprache:
eng 
Print-ISSN:
0923-7534 
TUM Einrichtung:
Frauenklinik und Poliklinik